•  
  •  
 

Turkish Journal of Medical Sciences

Abstract

Background/aimː This study aims to investigate the prevalence of malignancy in patients with inflammatory bowel disease (IBD) followed up in a tertiary reference center.

Materials and methodsː IBD patients with at least 6 months of follow-up from the gastroenterology clinic between 2000 and 2022 wereevaluated retrospectively in a tertiary center. Patient information was obtained from the patient registration system.

Resultsː There were 697 patients in the study, 320 (45.9%) of these were female. The mean age of the patients at IBD diagnosis was 33.4± 13.1 years. The mean follow-up time was 93.1 ± 64.8 (median 84, IQR (25–75) (36–144)) months. IBD types were as; 315 (45.2%) hadulcerative colitis, and 382 (54.8%) had Crohn’s disease. Before the diagnosis of IBD, 10 patients (1.4%) had a history of malignancy. Theprevalence of malignancy after the diagnosis of IBD was 13 (1.9%). There was a relationship between malignancy and older age, higherBMI, and female sex in survival analysis (p < 0.05). There was no correlation with disease type and malignancy (p = 0.820). When thepatients who developed malignancy in IBD were compared in terms of the immunomodulators and biological agents used by the patients who did not develop malignancy, there was no statistical difference between the two groups (p > 0.05).

Conclusionː Older age, higher BMI, and female sex were found to be at risk for the development of malignancy in IBD, although norelationship was found with the use of immunomodulators, biological agents, or disease type.

Author ORCID Identifier

ZÜLAL İSTEMİHAN: 0000-0003-2961-2660

BİLGER ÇAVUŞ: 0000-0003-2203-4255

ALİ BARDAK: 0000-0002-3073-8538

AYŞE KIRKOĞLU: 0000-0003-1687-0273

CANSU KIZILTAŞ: 0000-0002-1599-914X

RÜVEYDA SİLAY: 0000-0003-1590-9930

İBRAHİM ŞENKAL: 0000-0002-4363-7197

ZİYA İMANOV: 0000-0003-4749-7328

KENAN NURİYEV: 0000-0003-3806-6200

AYNURE RÜSTEMZADE: 0000-0002-7763-1690

SEZEN GENÇ: 0000-0001-7552-3816

MİNE GÜLLÜOĞLU: 0000-0002-3967-0779

ASLI ÇİFCİBAŞI ÖRMECİ: 0000-0001-6297-8045

KADİR DEMİR: 0000-0002-5226-3705

FATİH BEŞIŞIK: 0000-0001-5184-376X

SABAHATTİN KAYMAKOĞLU: 0000-0003-4910-249X

FİLİZ AKYÜZ: 0000-0001-7498-141X

DOI

10.55730/1300-0144.6036

Keywords

Biologics, immunomodulators, inflammatory bowel disease, malignancy

First Page

846

Last Page

854

Publisher

The Scientific and Technological Research Council of Türkiye (TÜBİTAK)

Creative Commons License

Creative Commons Attribution 4.0 International License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Download

Share

COinS